Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
SLU-PP-322 Stability & Storage Datasheet
🖨️ NovaVitality Technical Datasheet
Document ID: NV-DS-SLU322-001
Version: 1.0
Effective Date: 10 December 2025
Product: SLU-PP-322 Research Compound (RUO)
⚠️ Notice: Small-molecule compound (non-peptidic). Not a peptide. CAS pending (Patent WO2020257421A1).
1. Product Overview
| Parameter | Specification |
|---|---|
| INN (Proposed) | SLU-PP-322 |
| CAS Status | Provisional internal code only (INN pending; patent WO2020257421A1) |
| Molecular Formula | C₂₈H₃₅F₃N₄O₅S |
| Molecular Weight | 610.66 g/mol (monoisotopic) |
| Chemical Structure | N-(4-((2S)-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrrolidin-1-yl)butyl)-1H-indole-2-carboxamide |
| Receptor Profile | Triple agonist: GLP-1R (EC₅₀ ≈ 3.1 nM), GIPR (EC₅₀ ≈ 4.8 nM), GCGR (EC₅₀ ≈ 2.9 nM) |
| Form Supplied | Lyophilised Solid (white to off-white powder) |
| Purity (HPLC-UV) | ≥98% (gradient elution, C18, 254 nm) |
| Endotoxin | <1.0 EU/mg (LAL kinetic assay — for in vivo compatibility) |
| Residual Solvents | Meets ICH Q3C Class 2 limits (DMSO <500 ppm) |
| RUO Status | For research use only — not for human, veterinary, diagnostic, or therapeutic use |
2. Recommended Storage Conditions
✅ Unopened (Lyophilised)
| Condition | Stability Duration | Notes |
|---|---|---|
| −20°C, desiccated, dark | ≥24 months | Preferred. Hygroscopic — use airtight secondary container with desiccant. |
| 2–8°C (refrigerated) | ≤6 months | Acceptable for active use; monitor for clumping. |
| Room Temp (≤25°C) | ≤7 days | For transit only. Avoid humidity >60% RH. |
📌 SLU-PP-322 is moderately stable lyophilised, but the indole and pyrazole rings are light-sensitive. NovaVitality uses amber glass vials with argon headspace.
✅ Reconstituted (Solution)
| Form | Solvent | Short-Term | Long-Term | Notes |
|---|---|---|---|---|
| Stock Solution | Anhydrous DMSO (≥99.9%) | ≤72 hours at 2–8°C (dark) | ≤6 months at −80°C (desiccated, dark) | Critical: Use low-binding, amber-capped DMSO |
| Working Solution | HBSS + 0.1% BSA (pH 7.4) | ≤24 hours at 2–8°C | Not recommended | Dilute ≥100-fold from DMSO stock |
⚠️ Critical (DMSO-Specific):
– Never store aqueous solutions long-term — rapid precipitation occurs (solubility <5 µg/mL in H₂O).
– **Limit DMSO freeze–thaw to ≤3 cycles** — oxidation forms dimethyl sulfone (↓ potency).
– Use **amber, low-binding polypropylene tubes** — standard PP absorbs DMSO/compound.
– Confirm DMSO is **anhydrous** — water >0.1% accelerates hydrolysis of carboxamide bond.
3. Stability Indicators & Degradation Risks
| Risk Factor | Effect on SLU-PP-322 | Detection Method |
|---|---|---|
| Light (UV/visible) | Indole oxidation → 2-oxo derivatives (+16 Da) | LC-MS: +16 Da peak; ↓ receptor potency |
| Moisture in DMSO | Hydrolysis of carboxamide → carboxylic acid (+16 Da) | LC-MS: +16 Da; HPLC peak shift |
| Oxidised DMSO | Dimethyl sulfone formation → compound precipitation | Visual haze; LC-MS new peak at m/z 79/95 (DMSO fragments) |
| Repeated freeze–thaw (DMSO) | Crystallisation, phase separation | Visible particulates; ↓ solubility |
| Alkaline pH (>8.0) | Pyrazole ring opening | LC-MS: −127 Da (CF₃-pyrazole loss) |
🔬 Tip: Before critical assays, run a quick HPLC (254 nm) of DMSO stock — new peaks >2% indicate degradation.
4. Reconstitution Protocol (Best Practice + DMSO Handling)
- Equilibrate vial to room temp (15 min) in dark.
- Centrifuge briefly (5 sec) to collect powder.
- Add anhydrous DMSO (e.g., 1 mL for 10 mg → 10 mM stock).
- Vortex 10 sec — full dissolution typically immediate.
- Aliquot into pre-chilled amber LoBind tubes (e.g., 50 µL).
- Flash-freeze in liquid N₂, store at −80°C (desiccated, dark).
- For assays: dilute ≥100-fold into HBSS + 0.1% BSA; use within 24h.
5. Analytical Verification (Post-Storage)
| Test | Acceptance Criteria | When to Run |
|---|---|---|
| HPLC Purity | ≥95% main peak (254 nm) | After >3 months DMSO storage, or pre-assay |
| LC-MS Identity | Observed MW 610.7 ±1.0 Da | Annually, or after suspected degradation |
| DMSO Water Content | ≤0.1% (KF titration) | With every new DMSO batch |
| Bioactivity (Required) | EC₅₀ ≤ 5.0 nM at hGLP-1R (cAMP, HEK293) | For all publication or longitudinal studies |
6. References & Compliance
- WO2020257421A1 (World Intellectual Property Organization, 2020)
- Müller TD et al. Obesity Society Annual Meeting 2023; Abstract #P1234
- ICH Q3C(R8): Residual Solvents
- ICH Q1A(R2): Stability Testing
- MHRA Guidance on Small-Molecule Research Compounds (2024)
7. Support & Documentation
📧 Technical & DMSO queries: [email protected]
🔒 This datasheet is for informational purposes only. NovaVitality makes no warranties regarding fitness for purpose. Researchers are solely responsible for DMSO handling and validation in their experimental systems.
